On the public citation graph

A Dual-Functional Oncolytic Adenovirus Armed with Pd-L1 Inhibitor Potentiates its Antitumor Activity

https://doi.org/10.2139/ssrn.4652904
0 signed · 29 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s002620050512openalex-extracted
Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy
inferredcites →https://doi.org/10.1007/s11262-017-1488-1openalex-extracted
Oncolytic viruses: adenoviruses
inferredcites →https://doi.org/10.1016/j.cell.2017.01.017openalex-extracted
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
inferredcites →https://doi.org/10.1016/j.cell.2017.08.027openalex-extracted
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
inferredcites →https://doi.org/10.1016/j.copbio.2019.11.016openalex-extracted
Design and application of oncolytic viruses for cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.febslet.2013.10.015openalex-extracted
Checkpoint blocking antibodies in cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.immuni.2007.05.016openalex-extracted
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
inferredcites →https://doi.org/10.1016/j.immuni.2016.06.001openalex-extracted
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
inferredcites →https://doi.org/10.1016/j.it.2019.04.002openalex-extracted
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
inferredcites →https://doi.org/10.1016/j.trsl.2021.04.008openalex-extracted
Development of oncolytic viruses for cancer therapy
inferredcites →https://doi.org/10.1016/j.virol.2017.12.016openalex-extracted
Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding
inferredcites →https://doi.org/10.1038/gt.2016.70openalex-extracted
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy
inferredcites →https://doi.org/10.1038/nature22079openalex-extracted
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
inferredcites →https://doi.org/10.1038/ni.2703openalex-extracted
Innate and adaptive immune cells in the tumor microenvironment
inferredcites →https://doi.org/10.1038/s41419-020-2236-3openalex-extracted
Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-extracted
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1080/2162402x.2017.1365209openalex-extracted
PD-L1 inhibitors in the pipeline: Promise and progress
inferredcites →https://doi.org/10.1080/21645515.2016.1249551openalex-extracted
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors
inferredcites →https://doi.org/10.1089/hum.2014.001openalex-extracted
Innate Immunity to Adenovirus
inferredcites →https://doi.org/10.1097/01.cji.0000436722.46675.4aopenalex-extracted
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
inferredcites →https://doi.org/10.1111/1759-7714.13043openalex-extracted
Updates to the antitumor mechanism of oncolytic virus
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-1507openalex-extracted
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-2569openalex-extracted
Immunotherapy for Breast Cancer: What Are We Missing?
inferredcites →https://doi.org/10.1177/1756284820917527openalex-extracted
Advances in immunotherapy for colorectal cancer: a review
inferredcites →https://doi.org/10.2217/imt.14.86openalex-extracted
Current Advances in T-Cell-Based Cancer Immunotherapy
inferredcites →https://doi.org/10.3389/fimmu.2020.01624openalex-extracted
Colorectal Cancer Immunotherapy: Options and Strategies
inferredcites →https://doi.org/10.3389/fphar.2017.00730openalex-extracted
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
inferredcites →https://doi.org/10.4103/0019-509x.82887openalex-extracted
The role of innate immunity in spontaneous regression of cancer
inferredcites →https://doi.org/10.4103/0976-9668.82318openalex-extracted
Immunity over inability: The spontaneous regression of cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.